Centogene (CNTGF)
OTHER OTC:CNTGF
Top Page
No summary available
Positive Factors
Business Model Strength
Centogene's business model leverages its expertise in rare disease diagnostics and genetic testing, providing stable revenue streams through long-term contracts and collaborative research agreements with pharmaceutical companies.
Negative Factors
High Leverage
High leverage poses a risk to Centogene's financial health, limiting its ability to invest in growth opportunities and increasing vulnerability to economic downturns, which could impact long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Business Model Strength
Centogene's business model leverages its expertise in rare disease diagnostics and genetic testing, providing stable revenue streams through long-term contracts and collaborative research agreements with pharmaceutical companies.
Read all positive factors
Centogene (CNTGF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.58M
Dividend YieldN/A
Average Volume (3M)1.26K
Price to Earnings (P/E)―
Beta (1Y)-3.02
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees493
SectorHealthcare
Sector Strength45
IndustryMedical Diagnostics & Screening
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,817,080
10 Day Avg. Volume717
30 Day Avg. Volume1,260
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Centogene Business Overview & Revenue Model
Company Description
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two se...
How the Company Makes Money
Centogene generates revenue primarily through its diagnostic services and collaborations with pharmaceutical companies. The company offers a wide range of genetic testing services, including whole exome and genome sequencing, which are utilized by...
Centogene Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | 17.25M | 19.76M | 28.16M | 44.94M | 22.77M |
| EBITDA | -20.48M | -55.30M | -24.73M | -4.93M | -12.09M |
| Net Income | -35.53M | -63.83M | -92.62M | -21.38M | -20.86M |
Balance Sheet | |||||
| Total Assets | 77.16M | 92.81M | 90.69M | 150.13M | 117.51M |
| Cash, Cash Equivalents and Short-Term Investments | ― | ― | ― | ― | ― |
| Total Debt | 80.73M | 60.12M | 22.81M | 24.10M | 26.97M |
| Total Liabilities | 102.44M | 88.71M | 65.90M | 84.35M | 58.59M |
| Stockholders Equity | ― | ― | ― | ― | ― |
Cash Flow | |||||
| Free Cash Flow | -33.94M | 4.00M | -27.23M | -8.09M | -15.35M |
| Operating Cash Flow | -31.75M | 5.23M | -21.70M | 8.46M | -7.78M |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
Centogene Technical Analysis
Positive
0.12
Price Trends
0.11
Positive
0.11
Positive
0.10
Positive
Market Momentum
<0.01
Negative
60.93
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTGF, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.11, and above the 200-day MA of 0.10, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.93 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTGF.
Centogene Risk Analysis
Centogene disclosed 88 risk factors in its most recent earnings report. Centogene reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Centogene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $3.58M | ― | 140.54% | ― | ― | ― | |
46 Neutral | $1.72M | >-0.01 | 2.66% | ― | -27.81% | ― | |
45 Neutral | $3.40M | -0.28 | -191.39% | ― | ― | 76.53% | |
43 Neutral | $3.68M | -0.12 | -215.04% | ― | -100.00% | 93.82% | |
42 Neutral | $3.71M | -0.10 | -262.78% | ― | ― | 79.45% | |
42 Neutral | $4.35M | -0.22 | -0.40% | ― | ― | 96.26% |
* Healthcare Sector Average
CNTGF
Centogene
0.12
-0.03
-17.81%
AEMD
Aethlon Medical
2.20
-25.86
-92.16%
ENVB
Enveric Biosciences
1.97
-12.94
-86.79%
REVB
Revelation Biosciences
1.19
-35.41
-96.75%
UPC
Universe Pharmaceuticals
3.13
-0.18
-5.44%
AZTR
Azitra Inc
0.21
-1.73
-89.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―